BlossomHill Therapeutics, Inc. (BLSM) · INSIDERData sourcesSEC Form 45h ago
House PTR5h ago
SEC 13F5h ago
Robinhood Chain4h ago
Public companyBlossomHill Therapeutics, Inc.
BLSMCIK 0001839970
Price$13.50
1 year-15.6%
Disclosed transactions25
Buys / sells3 / 0
Max Insider Score46
Connections with evidence7
BLSM · disclosed activity on price
| Score | Actor | Security | Side | Value | Executed | Disclosed | Lag | Source | Evidence |
|---|
| 9 | ASAgrawal SundeepDirector | BLSMBlossomHill Therapeutics, Inc. Grant or award | A | — 23.9K sh | Aug 6, 2026 | Aug 10, 2026 |
| 9 | ASAgrawal SundeepDirector | BLSMBlossomHill Therapeutics, Inc. Derivative conversion | C | — 578.5K sh | Aug 10, 2026 | Aug 10, 2026 traded Aug 10, 2026 | +0d | SEC Form 4 | |
| 9 | CJCui Jingrong JeanDirector, President and CEO, 10% Owner | BLSMBlossomHill Therapeutics, Inc. Derivative conversion | C | — 124.8K sh | Aug 10, 2026 | Aug 10, 2026 traded Aug 10, 2026 | +0d | SEC Form 4 | |
| 9 | CJCui Jingrong JeanDirector, President and CEO, 10% Owner | BLSMBlossomHill Therapeutics, Inc. Grant or award | A | — 676.2K sh | Aug 6, 2026 | Aug 10, 2026 traded Aug 6, 2026 | +4d | SEC Form 4 | |
| 9 | CJCui Jingrong JeanDirector, President and CEO, 10% Owner | BLSMBlossomHill Therapeutics, Inc. Derivative conversion | C | — 1.60M sh | Aug 10, 2026 | Aug 10, 2026 traded Aug 10, 2026 | +0d | SEC Form 4 | |
| 9 | CJCui Jingrong JeanDirector, President and CEO, 10% Owner | BLSMBlossomHill Therapeutics, Inc. Derivative conversion | C | — 113.4K sh | Aug 10, 2026 | Aug 10, 2026 traded Aug 10, 2026 | +0d | SEC Form 4 | |
| 9 | CJCui Jingrong JeanDirector, President and CEO, 10% Owner | BLSMBlossomHill Therapeutics, Inc. Derivative conversion | C | — 124.8K sh | Aug 10, 2026 | Aug 10, 2026 traded Aug 10, 2026 | +0d | SEC Form 4 | |
| 9 | LYLi YishanDirector, Executive Chairman, 10% Owner | BLSMBlossomHill Therapeutics, Inc. Derivative conversion | C | — 124.8K sh | Aug 10, 2026 | Aug 10, 2026 traded Aug 10, 2026 | +0d | SEC Form 4 | |
| 30 | LPLiptak Vincent PaulGeneral Counsel | BLSMBlossomHill Therapeutics, Inc. Open-market purchase | BUY | $35K 2,200 sh | Aug 10, 2026 | Aug 10, 2026 traded Aug 10, 2026 | +0d | SEC Form 4 | |
| 9 | OROxnard Geoffrey RaymondChief Medical Officer | BLSMBlossomHill Therapeutics, Inc. Grant or award | A | — 61.8K sh | Aug 6, 2026 | Aug 10, 2026 traded Aug 6, 2026 | +4d | SEC Form 4 | |
| 5 | LPLiptak Vincent PaulGeneral Counsel | BLSMBlossomHill Therapeutics, Inc. Derivative conversion | C | — 22.7K sh | Aug 10, 2026 | Aug 10, 2026 traded Aug 10, 2026 | +0d | SEC Form 4 | |
| 9 | LPLiptak Vincent PaulGeneral Counsel | BLSMBlossomHill Therapeutics, Inc. Grant or award | A | — 46.6K sh | Aug 6, 2026 | Aug 10, 2026 traded Aug 6, 2026 | +4d | SEC Form 4 | |
| 9 | CJCui Jingrong JeanDirector, President and CEO, 10% Owner | BLSMBlossomHill Therapeutics, Inc. Derivative conversion | C | — 1.60M sh | Aug 10, 2026 | Aug 10, 2026 traded Aug 10, 2026 | +0d | SEC Form 4 | |
| 9 | KAKeyes Jason AChief Financial Officer | BLSMBlossomHill Therapeutics, Inc. Grant or award | A | — 56.7K sh | Aug 6, 2026 | Aug 10, 2026 traded Aug 6, 2026 | +4d | SEC Form 4 | |
| 9 | LYLi YishanDirector, Executive Chairman, 10% Owner | BLSMBlossomHill Therapeutics, Inc. Derivative conversion | C | — 113.4K sh | Aug 10, 2026 | Aug 10, 2026 traded Aug 10, 2026 | +0d | SEC Form 4 | |
| 9 | LYLi YishanDirector, Executive Chairman, 10% Owner | BLSMBlossomHill Therapeutics, Inc. Derivative conversion | C | — 124.8K sh | Aug 10, 2026 | Aug 10, 2026 traded Aug 10, 2026 | +0d | SEC Form 4 | |
| 5 | LPLiptak Vincent PaulGeneral Counsel | BLSMBlossomHill Therapeutics, Inc. Derivative conversion | C | — 22.7K sh | Aug 10, 2026 | Aug 10, 2026 traded Aug 10, 2026 | +0d | SEC Form 4 | |
| 13 | CJCui Jingrong JeanDirector, President and CEO, 10% Owner | BLSMBlossomHill Therapeutics, Inc. Derivative conversion | C | — 113.4K sh | Aug 10, 2026 | Aug 10, 2026 traded Aug 10, 2026 | +0d | SEC Form 4 | |
| 34 | LPLiptak Vincent PaulGeneral Counsel | BLSMBlossomHill Therapeutics, Inc. Open-market purchase | BUY | $40K 2,500 sh | Aug 7, 2026 | Aug 10, 2026 traded Aug 7, 2026 | +3d | SEC Form 4 | |
| 9 | LYLi YishanDirector, Executive Chairman, 10% Owner | BLSMBlossomHill Therapeutics, Inc. Derivative conversion | C | — 1.60M sh | Aug 10, 2026 | Aug 10, 2026 traded Aug 10, 2026 | +0d | SEC Form 4 | |
| 13 | LYLi YishanDirector, Executive Chairman, 10% Owner | BLSMBlossomHill Therapeutics, Inc. Derivative conversion | C | — 113.4K sh | Aug 10, 2026 | Aug 10, 2026 traded Aug 10, 2026 | +0d | SEC Form 4 | |
| 9 | LYLi YishanDirector, Executive Chairman, 10% Owner | BLSMBlossomHill Therapeutics, Inc. Grant or award | A | — 112.7K sh | Aug 6, 2026 | Aug 10, 2026 traded Aug 6, 2026 | +4d | SEC Form 4 | |
| 9 | LYLi YishanDirector, Executive Chairman, 10% Owner | BLSMBlossomHill Therapeutics, Inc. Derivative conversion | C | — 1.60M sh | Aug 10, 2026 | Aug 10, 2026 traded Aug 10, 2026 | +0d | SEC Form 4 | |
| 9 | ASAgrawal SundeepDirector | BLSMBlossomHill Therapeutics, Inc. Derivative conversion | C | — 578.5K sh | Aug 10, 2026 | Aug 10, 2026 traded Aug 10, 2026 | +0d | SEC Form 4 | |
| 46 | KAKeyes Jason AChief Financial Officer | BLSMBlossomHill Therapeutics, Inc. Open-market purchase | BUY | $11K 700 sh | Aug 10, 2026 | Aug 10, 2026 traded Aug 10, 2026 | +0d | SEC Form 4 | |
Director, Executive Chairman, 10% Owner · Aug 10, 2026